Cite
Everolimus-eluting bioresorabable scaffold system in the treatment of cardiac allograft vasculopathy: the cardiac allograft reparative therapy (CART) prospective multicentre pilot study
MLA
M Pighi, et al. “Everolimus-Eluting Bioresorabable Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: The Cardiac Allograft Reparative Therapy (CART) Prospective Multicentre Pilot Study.” European Heart Journal, vol. 43, Oct. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ee2a210171e69482b532955961dee15a&authtype=sso&custid=ns315887.
APA
M Pighi, F Tomai, S Fezzi, G Pesarini, A Petrolini, L Spedicato, G Tarantini, M Ferlini, P Calabro, B Loi, N Tovar Forero, J Daemen, & F T Ribichini. (2022). Everolimus-eluting bioresorabable scaffold system in the treatment of cardiac allograft vasculopathy: the cardiac allograft reparative therapy (CART) prospective multicentre pilot study. European Heart Journal, 43.
Chicago
M Pighi, F Tomai, S Fezzi, G Pesarini, A Petrolini, L Spedicato, G Tarantini, et al. 2022. “Everolimus-Eluting Bioresorabable Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: The Cardiac Allograft Reparative Therapy (CART) Prospective Multicentre Pilot Study.” European Heart Journal 43 (October). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ee2a210171e69482b532955961dee15a&authtype=sso&custid=ns315887.